Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)
This prescription-only medication belongs to a class of medicines called GLP-1 receptor agonists and helps lower blood sugar (A1C) when used alongside diet and exercise
Long-term data is also needed because widespread GLP-1 use is still relatively recent
[1] Our Score: 3/5 Our score is based on the latest medical data, customer feedback, and clinic policies
These include compounds from various pharmaceutical research programs exploring different balance ratios across the three target receptors
Once your order ships, youll receive a confirmation email containing tracking information so you can monitor delivery progress
.png.jpg)
US$ 28.42
US$ 23.61
US$ 27.48
US$ 22.60
US$ 28.06
US$ 27.56
